carmat sa (ALCAR) ISIN: FR0010907956

[alles kan beter]

* CONFIRMS THE FIRST SUCCESSFUL HEART TRANSPLANT OF A
PATIENT
PREVIOUSLY IMPLANTED WITH ITS TOTAL ARTIFICIAL HEART
* WORLD PREMIERE HEART TRANSPLANT PERFORMED AFTER 8 MONTHS
OF
SUCCESSFUL SUPPORT PROVIDED BY CARMAT BIOPROSTHESIS
* IMPLANT OF CARMAT DEVICE WAS PERFORMED IN OCTOBER 2017
* PRIMARY OBJECTIVE OF PIVOTAL STUDY WAS LARGELY MET FOR
THIS
PATIENT

[Blackadder]

https://www.finanzen.nl/aandelen/carmat-aandeel-koers

[alles kan beter]

- Carmat a confirmé l’annonce du National Research Center for Cardiac Surgery (Astana, Kazakhstan) sur le succès de la transplantation avec un cœur de donneur du premier patient international qui a été implanté avec le cœur Carmat en octobre 2017.Le patient souffrant d’insuffisance cardiaque terminale n’était initialement pas éligible à la transplantation cardiaque dû à son hypertension pulmonaire.

L'implantation du dispositif Carmat a été réalisée en octobre 2017 dans le cadre de l'étude Pivot, en attente d'une transplantation.
Durant cette période de huit mois, l'état de santé du patient s'est considérablement amélioré grâce au soutien du dispositif Carmat qui lui a permis de se rétablir efficacement de son hypertension pulmonaire pour devenir éligible à une transplantation et, finalement, recevoir un cœur de donneur au mois de juin.
"L'objectif primaire de l'étude Pivot a été largement atteint pour ce patient, étant donné que le protocole de l'étude stipule une survie à 180 jours (soit six mois) après l'implantation ou une transplantation cardiaque réussie, en remplacement du dispositif, dans ce délai de 180 jours", souligne le groupe.

[alles kan beter]

+10 bij opening. mooi.

[alles kan beter]

15% op 2 dagen.
saai.

[alles kan beter]

blijft maar zakken. oorzaak...?

[alles kan beter]

* PRESENTS POSITIVE INTERIM RESULTS OF THE FIRST PART OF ITS
PIVOTAL STUDY
* CARMAT HAD CASH AND MARKETABLE CASH INSTRUMENTS OF EUR
25.2
MILLION AT DECEMBER 31, 2018
* 70% OF PATIENTS IN THIS FIRST COHORT REACHED STUDY'S
PRIMARY
ENDPOINT
* DATA CONFIRM BIOCOMPATIBILITY OF CARMAT PROSTHESIS
* COMPANY IS CURRENTLY VALIDATING ADDITIONAL CLINICAL
CENTERS IN
TWO MORE COUNTRIES IN ORDER TO RAPIDLY COMPLETE ENROLLMENT OF
SECOND PATIENT COHORT AND SUBMIT CE MARKING DOSSIER IN EARLY
2020
* CARMAT HAD CASH AND MARKETABLE CASH INSTRUMENTS OF EUR
25.2
MILLION AT DECEMBER 31, 2018, VERSUS EUR 44.0 MILLION AT JUNE
30, 2018
* CASH BURN OF EUR 19.7 MILLION OVER PERIOD
* ACCESS TO AN ADDITIONAL EUR 24.2 MILLION OF FINANCING

Source text for Eikon:
Further company coverage:

[alles kan beter]

French artificial heart maker Carmat prepares for commercial launch in Q2
07:12 (06/01) - Bron: Reuters
PARIS, Jan 6 (Reuters) - French artificial heart maker
Carmat said on Wednesday that it was preparing for
the commercial launch of its products in the second quarter of
this year, in a European market which could have at least 2,000
patients a year.
Carmat said its artificial heart would be marketed under the
brand name of "Aeson". Aeson would be launched commercially in
Germany in the second quarter, while the French market would be
targeted around the same time.
"I am happy to confirm that we will be ready to start
selling our product as early as Q2 2021," said Carmat chief
executive Stephane Piat.


(Reporting by Sudip Kar-Gupta; Editing by Jacqueline Wong)
((sudip.kargupta@thomsonreuters.com; +33 1 49 49 53 84;))